Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study.
Olanow, C Warren ; Kieburtz, Karl ; Odin, Per LU
; Espay, Alberto J
; Standaert, David G
; Fernandez, Hubert H
; Vanagunas, Arvydas
; Othman, Ahmed A
; Widnell, Katherine L
and Robieson, Weining Z
, et al.
(2014)
In Lancet Neurology
13(2).
p.141-149
- Abstract
- Levodopa is the most effective therapy for Parkinson's disease, but chronic treatment is associated with the development of potentially disabling motor complications. Experimental studies suggest that motor complications are due to non-physiological, intermittent administration of the drug, and can be reduced with continuous delivery. We aimed to assess efficacy and safety of levodopa-carbidopa intestinal gel delivered continuously through an intrajejunal percutaneous tube.
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/4223335
- author
- Olanow, C Warren
; Kieburtz, Karl
; Odin, Per
LU
; Espay, Alberto J
; Standaert, David G
; Fernandez, Hubert H
; Vanagunas, Arvydas
; Othman, Ahmed A
; Widnell, Katherine L
and Robieson, Weining Z
, et al. (More)
- Olanow, C Warren
; Kieburtz, Karl
; Odin, Per
LU
; Espay, Alberto J
; Standaert, David G
; Fernandez, Hubert H
; Vanagunas, Arvydas
; Othman, Ahmed A
; Widnell, Katherine L
; Robieson, Weining Z
; Pritchett, Yili
; Chatamra, Krai
; Benesh, Janet
; Lenz, Robert A
and Antonini, Angelo
(Less)
- author collaboration
- organization
- publishing date
- 2014
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Lancet Neurology
- volume
- 13
- issue
- 2
- pages
- 141 - 149
- publisher
- Lancet Publishing Group
- external identifiers
-
- pmid:24361112
- wos:000330546200009
- scopus:84892516916
- ISSN
- 1474-4465
- DOI
- 10.1016/S1474-4422(13)70293-X
- language
- English
- LU publication?
- no
- id
- 4eecb177-b554-4e6f-8c5b-c1565e425994 (old id 4223335)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/24361112?dopt=Abstract
- date added to LUP
- 2016-04-01 10:42:45
- date last changed
- 2022-12-10 01:41:29
@article{4eecb177-b554-4e6f-8c5b-c1565e425994,
abstract = {{Levodopa is the most effective therapy for Parkinson's disease, but chronic treatment is associated with the development of potentially disabling motor complications. Experimental studies suggest that motor complications are due to non-physiological, intermittent administration of the drug, and can be reduced with continuous delivery. We aimed to assess efficacy and safety of levodopa-carbidopa intestinal gel delivered continuously through an intrajejunal percutaneous tube.}},
author = {{Olanow, C Warren and Kieburtz, Karl and Odin, Per and Espay, Alberto J and Standaert, David G and Fernandez, Hubert H and Vanagunas, Arvydas and Othman, Ahmed A and Widnell, Katherine L and Robieson, Weining Z and Pritchett, Yili and Chatamra, Krai and Benesh, Janet and Lenz, Robert A and Antonini, Angelo}},
issn = {{1474-4465}},
language = {{eng}},
number = {{2}},
pages = {{141--149}},
publisher = {{Lancet Publishing Group}},
series = {{Lancet Neurology}},
title = {{Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study.}},
url = {{http://dx.doi.org/10.1016/S1474-4422(13)70293-X}},
doi = {{10.1016/S1474-4422(13)70293-X}},
volume = {{13}},
year = {{2014}},
}